1. Pink Sheet
  2. >>Pathways & Standards

Biogen Gets ‘Almost Shockingly Broad’ Label For Alzheimer’s Drug Aducanumab

 
• By Brenda Sandburg

US FDA’s Peter Stein says drug’s mechanism of action is relevant to all stages of Alzheimer’s disease. While clinical trials enrolled only those with mild disease as indicated on a PET scan, labeling has no limitations on use of Aduhelm. An FDA advisory committee member resigns from the panel in response to the approval.

Alzheimer's
FDA approves Alzheimer's drug Aducanumab for all stages of the disease. • Source: Alamy

The labeling for Biogen, Inc. and Eisai Co., Ltd.’s Aduhelm (aducanumab) came as a big surprise to those awaiting US Food and Drug Administration action on the drug as it does not limit use to those showing early symptoms from Alzheimer’s disease or require pre-screening of patients, conditions that had to be met for participants in two Phase III clinical trials for the drug.

The label states that Aduhelm “is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease

In a 7 June press briefing announcing the approval, the FDA was asked why it decided to go with such a broad label

More from Approval Standards

More from Pathways & Standards

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

UK’s International Recognition Procedure: EU Dossier Faster Than US Or Canada

 
• By Eliza Slawther

Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.

HHS Secretary Kennedy Says Trump Will Make Final Decision On Mifepristone Policy

 
• By Derrick Gingery

With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.